| Data collection
HTC staff collected data at annual comprehensive clinic visits. Date of birth (used to calculate age at the time of the visit) and self-identified race and ethnicity data were collected at the initial UDC visit. For the analysis, a combined race/ethnicity variable was created with four levels: non-Hispanic white, non-Hispanic black, Hispanic, and other race ethnicities. Other sociodemographic data, including type of health insurance and whether the participant was employed or a student, were collected at each UDC visit. Clinical information collected during visits included measurements of height and weight; the type of treatment regimen (prophylaxis vs episodic); the highest inhibitor titre measured since the last UDC visit; whether the patient was on an immune tolerance treatment regimen; the number of joint, muscle or other bleeds experienced in the previous 6 months; the presence of signs or symptoms of liver disease (e.g, jaundice, ascites, varices), elevated liver enzymes, or evidence of previous infection with hepatitis B or C; the presence of a target joint (following the UDC definition as 4 or more bleeds in the same joint in the previous 6 months); the number of days missed from work or school due to a joint problem; use of a cane or other assistive device for ambulation; and self-reported current activity level. The presence of HIV infection was determined on the basis of blood testing performed at the CDC laboratory as part of the surveillance. 12 
| Data analysis
For the analysis, we converted height and weight to body mass index (BMI) by dividing weight by height squared and categorized body weight as normal (BMI<25 kg/m 2 ) for patients aged ≥20 years or according to CDC BMI charts for patients aged <20 years. 13 Only patients who had a recent inhibitor titre >1 Bethesda Unit or who were on an immune tolerance treatment regimen at the time of the visit were defined as having an inhibitor for the study. Insurance type was collapsed into two categories: commercial vs any other type of insurance or none.
We created three indicators for the following outcomes based on the empirical distribution of the present data:
• Severe bleeding was defined as ≥5 joint or total bleeds in the previous 6 months or as having one or more target joints (a joint with ≥4
bleeds in the previous 6 months);
• Liver disease was defined as the presence of either signs/symptoms of liver disease, or elevated liver enzymes, or hepatitis B-or C-positive serologic status;
• Joint disease was defined as having a decreased activity level (either has limitations in or requires assistance with school/work, recreation and self-care), or ≥10 missed days of work or school due to a joint problem, 14 or continuous use of a cane or a wheelchair for ambulation. instrument. The first completed questionnaire was used for those who completed more than one questionnaire, and data on other characteristics and outcomes were taken from the UDC visit at which the questionnaire was completed.
Conversion of the raw survey scores to HSUVs for each survey was accomplished using computer programs that applied country-specific weights to the survey question response levels. The EQ-5D HSUVs were derived using a US population value set 15 (using software authored by James W. Shaw and available at: https://www.ahrq.gov/ professionals/clinicians-providers/resources/rice/ceoutc.html#Euro-Qol), whereas the SF-6D HSUVs were derived from the SF ® health survey using the original UK. population value set 16 (using software licensed from Sheffield University Enterprises Ltd., Sheffield, UK) as a US value set was not available.
| Statistical analysis
Data from all UDC participants with severe haemophilia A completing at least one HRQoL questionnaire were included in the analyses.
Because the HSUVs for participants were not normally distributed, Wilcoxon score comparisons using nonparametric regression analyses were used to assess differences in utility values between levels of the sociodemographic and clinical characteristics for statistical significance. Collinearity diagnostics revealed no indication of multicollinearity between variables; however, statistical interaction between age and several of the variables was identified. Therefore, the results of regression analyses were stratified by three age groups: 14-20, 21-44 and 45+ years to allow for potential age differences in influences of the studied risk factors on HRQoL.
All analyses used SAS statistical software (SAS Institute, Cary, NC, USA), and P-values ≤.05 were considered statistically significant. Any differences in SF-6D scores <0.03 and differences in EQ-5D scores <0.04 were considered to be not "minimally important" and hence not of clinical significance. The minimally important difference (MID) for a patient-reported outcome measure is the smallest difference that a patient would be likely to perceive as beneficial. 17 In the case of multi-attribute utility instruments like the SF-6D and the EQ-5D, the MID is measured as the smallest difference in HSUV associated with a one-step change in the underlying health state classification system. 18 A US study that used that approach found that the mean MID was 0.027 for the SF-6D and 0.040 for the EQ-5D using the US preference function or value set. 18 
| RESULTS
The study population comprised 1859 males with severe haemophilia A with at least one completed HRQoL survey. One-third of patients were under age 21 years and one-half between 21 and 44 years old (Table 1 ). Compared to the US population, 19 Hispanic ethnicity was under-represented. One-half had commercial insurance, while onethird had public (Medicare or Medicaid) insurance. Two-thirds were employed or attended school. Nearly half were overweight or obese.
Nearly 40% were on a prophylactic regimen, and 6.7% of the patients had a current inhibitor. About one-fourth were HIV-infected, twothirds had an indicator of liver disease, and one-half had joint disease or severe bleeding ( Table 1 ). The respondents represented 51.6% of the 3603 otherwise eligible patients during the same time period.
Those who completed the questionnaire were somewhat younger, less likely to be a minority and less likely to be uninsured than the non-respondents. Respondents also less often had inhibitors than did non-respondents.
In bivariate analyses, sociodemographic, treatment and clinical characteristics except body adiposity were significantly associated with at least one of the two HSUVs (Table 1 ). The average HSUVs were generally higher for the EQ-5D measure than for the SF-6D, but the relative differences in average HSUVs among levels of the characteristics were similar. Average HSUVs decreased with age but increased for patients with commercial vs other types of insurance, those who were students or employed, those who were on prophylaxis, those who were not HIV-infected, and those without evidence of severe bleeding, joint disease or liver disease.
Average HSUVs were slightly lower for the SF-6D (0.04 lower) and EQ-5D (0.03 lower) measures in patients with a current inhibitor than in those without an inhibitor ( Table 1 ). The magnitudes of both differences were of marginal clinical significance, although the difference in the SF-6D HSUV exceeds the MID, whereas the EQ-5D HSUV does not. All other differences in Table 1 that were statistically significant were of clinical significance, with differences ≥0.04 exceeding the MID for both measures.
One patient characteristic, a dichotomous variable for joint disease, was independently and negatively associated with HSUVs in multivariate analyses (indicated by negative values for the coefficients)
across both measures and all three age groups ( Table 2 ).
The only other characteristic that was significantly associated with HRQoL across both measures within two age groups was student/employment status. Among patients under age 45 years, being The adjusted mean HSUVs are presented for patients with and without an inhibitor in Table 3 . Although the mean EQ-5D HSUVs were uniformly higher than those from the SF-6D, differences were very small, and the HSUVs differed very little by inhibitor status or across age groups.
| DISCUSSION
Among a large group of patients with severe haemophilia A, we found relatively consistent effects on HRQoL associated with several sociodemographic and clinical characteristics as assessed by two preferencebased HRQoL measures, the EQ-5D and SF-6D. Most importantly, patients with indicators of joint disease had substantially decreased HRQoL within each age group. Adolescents and adults under age 45 who were students or were employed had significantly better HSUVs.
Patients with commercial insurance generally had higher HSUVs than those with other forms of insurance but the association was too modest to be of clinical significance for those under age 45. 18 The impact of joint disease on HRQoL is marked. Our results suggest that this risk factor alone is primarily responsible for the decreased HRQoL observed in persons with severe haemophilia. The adjusted and unadjusted impact of joint disease on EQ-5D HSUVs is virtually the same, about −0.13 (Tables 1 and 2 ). That is almost equal in absolute magnitude to the 0.15 difference in mean EQ-5D HSUVs observed between the 14-20 and 45+ year age groups. An important implication is that the presence of joint disease should be accounted for in analyses of the effects of other variables on HRQoL among persons with haemophilia, especially when using the EQ-5D, which includes a mobility component.
Of Several other characteristics, including liver disease, BMI and HIV infection, likewise were not independently associated with HRQoL.
BMI had no association with HRQoL even without controlling for confounding, whereas persons with either liver disease or HIV had significantly worse HRQoL on average before controlling for confounding (Table 1) . After controlling for other patient characteristics, though, neither factor had a significant association with HRQoL. In a preliminary multivariate regression analysis for the pooled sample, liver disease was strongly negatively associated with HRQoL (results not reported), but that association essentially disappeared when the analysis was stratified by age group (Table 2) . One possible explanation is that liver disease is strongly associated with older age, particularly over age 45 years, among whom HRQoL is generally lower than that among individuals in the younger age groups. Within age groups, liver disease was not associated with HRQoL.
Individuals using prophylaxis had significantly better average HRQoL than those who received on-demand factor, and prophylaxis status was slightly more strongly associated with HRQoL than was severe bleeding (Table 1) . However, younger subjects were much more likely than older subjects to be on prophylaxis and to have higher HSUVs. After adjusting for patient characteristics, prophylaxis status was not associated with HRQoL past age 20 years. Prophylaxis was weakly positively associated with HRQoL in the youngest age group, but only for one measure, the EQ-5D. Cross-sectional associations of current prophylaxis status and HRQoL typically do not differ statistically significantly, but the profile of prophylaxis over time may be more important. 8 Primary prophylaxis, initiated before the onset of severe bleeds, greatly reduces the risk of joint disease, the primary predictor of HRQoL in patients with severe haemophilia. Noone, et al. 11 reported a mean EQ-5D HSUV of 0.798 for 13 males with an inhibitor, which was higher than in our study, but the authors did not report a pooled HSUV for males without an inhibi- Third, many of the patients that we studied with a more severe bleeding phenotype were likely to have chosen to utilize prophylaxis, which is readily available to patients in this clinical setting. Therefore, to the extent that subjects who chose not to use prophylaxis despite frequent bleeding were less concerned with this complication, we may have underestimated the effect of frequent bleeding episodes on
HRQoL.
Finally, all of the patients participating in the surveillance receive care in the US HTC Network and have access to comprehensive haemophilia care and a variety of therapies including immune tolerance therapy treatment and bypassing products. It is possible that access to these therapies may have minimized any effects of inhibitors on
In conclusion, we found no consistent effect of an inhibitor on HRQoL after adjusting for the effects of other comorbid conditions, especially joint disease. The adjusted HSUVs we report may be useful in calculations of quality-adjusted life years (QALYs) for costeffectiveness or cost-utility studies needed to assess improvements in health for people with haemophilia resulting from therapeutic strategies such as prophylaxis. Adjusted for all characteristics studied (Table 2) .
T A B L E 3 Adjusted a mean preferencebased utility scores of 1859 males with severe haemophilia A as measured by the SF-6D and the EQ-5D for those with and without an inhibitor by age group
